Site Map
Home Page
Professional
Patient
About Neutropenia
First Cycle Neutropenic Events
Chemotherapy Regimen Risk
Proactive Risk Assessment
Facts About Neutropenia
About Neulasta
®
First Cycle Protection
Safety Information
Dosage and Administration
Frequently Asked Questions
Neulasta
®
Fact Sheet
Reimbursement Information
Reimbursement Connection
®
Professional Resources
Medical Information Connection™
Links
Important Product Safety Information
Contact Us
Privacy Statement
Terms of Use
About Low White Blood Cell Counts
Who is Most at Risk?
Understanding Your Blood Counts
How Neulasta
®
Can Help
Helping to Protect Against Infection
Questions to Ask Your Doctor
Support and Resources
Patient Assistance
ChemoCoach
®
Newsletters
Information on Neutropenia and Cancer
Glossary of Terms
Important Safety Information
Neulasta<sup>®</sup> (pegfilgrastim) is prescribed to reduce the risk of infection (initially marked by fever) in patients with some tumors receiving strong chemotherapy that decreases the number of infection-fighting white blood cells.
Amgen.com
|
Chemotherapy.com
© 2009 Amgen. All rights reserved.
Neulasta
®
Product Information
